SCHEMBL19289957

SCHEMBL19289957

CC(I)N[C@@H](Cc1ccccc1)C(=O)Nc1cccc(C#N)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MAPK1 P28482 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ PPIA P62937 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ MAPT P10636 2/20 0.45
▸ CCR3 P51677 3/20 0.45
▸ PDK1 Q15118 1/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ PDK3 Q15120 1/20 0.45
▸ PDK4 Q16654 1/20 0.45
▸ GPR34 Q9UPC5 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ DUSP3 P51452 1/20 0.43
▸ GRM4 Q14833 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18435161 0.91 LMNA (0.57) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL18435159 0.91 LMNA (0.57) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL16254307 0.86 LMNA (0.60) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL19289959 0.84 MEN1 (0.52) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL4163972 0.81 TACR1 (0.64) —
SCHEMBL16254339 0.79 LMNA (0.62) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL18197715 0.78 MAPT (0.57) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL7384641 0.76 LMNA (0.58) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL4599032 0.75 MAPT (0.60) LMNASMN1; SMN2MAPK1HSD17B10L3MBTL1
SCHEMBL16252298 0.74 MEN1 (0.55) SMN1; SMN2MAPK1ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861581-B9 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. BRISTOL MYERS SQUIBB CO (US) 2017-08-30 — — EP disclosed
Send feedback